Ningbo Qianwan Emerging Industry Venture Capital

Public records identify Shi Tianjie as the Executive Director and legal representative. Day-to-day investment authority is exercised through Shi, while ultimate control rests with the Ningbo Qianwan New Area Management Committee, which is the firm's founder and sole controlling shareholder. No additional investment committee members are publicly named.

The firm is backed entirely by the Ningbo Qianwan New Area Management Committee, a government administrative body for the Hangzhou Bay development zone in Zhejiang. As a corporate investor rather than a fund manager, it deploys balance sheet capital directly rather than calling capital from third-party limited partners. The exact capitalization has not been disclosed.

The Hangzhou Bay Life Science Park is a core anchored asset within the firm's portfolio, developed in partnership with Pharmaron Beijing Co., Ltd. The firm serves simultaneously as an investor in the park and as a provider of venture capital to tenant companies, creating a vertically integrated model where the park itself functions as an origination engine for early-stage life science investments. Pharmaron participates as a strategic partner and co-investor in associated funds.

No. While the Hangzhou Bay Life Science Park gives life sciences and healthcare services a prominent footprint, the firm's investment mandate extends across emerging industries that align with national and regional priorities. Additional focus areas include advanced manufacturing, robotics, automation, new energy, enterprise software, and mobility, with co-investment activity alongside NIO Capital confirming an active stance in the electric vehicle and smart mobility sectors.

Available records indicate a dual strategy. The firm makes direct equity investments into portfolio companies, particularly those seeded within the Hangzhou Bay development zone, while also participating as a limited partner in venture funds alongside partners such as Pharmaron. Direct investment is the structurally important mode, since the firm's mission includes populating physical industrial parks with operating companies — making direct stakes more strategically aligned than passive fund commitments alone.

Co-investment is a demonstrated part of the strategy. The firm has co-invested with NIO Capital in emerging industry transactions within the Ningbo regional network and maintains a fund co-investment relationship with Pharmaron Beijing Co., Ltd. The firm appears to favor partners who can contribute operational or strategic value beyond capital — NIO Capital brings sector-specific expertise in smart mobility, while Pharmaron contributes pharmaceutical R&D and real estate development capabilities.

As a wholly government-owned corporate investor, Ningbo Qianwan Emerging Industry Venture Capital applies a blended mandate where financial returns coexist with regional development objectives. It can accept longer holding periods, lower immediate IRRs, and higher policy risk than a conventional venture capital fund, provided individual investments contribute to the target industry mix and employment base within the Qianwan New Area. This structural feature distinguishes it from independent Chinese VC firms, which operate under LP return obligations without a regional land-value or tax-base incentive.